在联邦咨询小组结束后,为了维持美国在新生儿筛查方面的领导地位,启动了一个新的联盟,目的是扩大对可治疗条件的公平检测。 A new coalition launched to sustain U.S. leadership in newborn screening after a federal advisory panel ended, aiming to expand testing for treatable conditions equitably.

美国医学遗传学和基因组学学院启动了新生儿筛查联盟,以便在联邦咨询委员会于2025年4月结束工作后,保持国家对新生儿筛查的领导。 The American College of Medical Genetics and Genomics has launched a Newborn Screening Coalition to maintain national leadership in newborn screening after a federal advisory committee ended in April 2025. 该联盟是在120多个利益攸关方提供投入后组建的,它将利用基于科学的透明程序,评估筛查的新条件,并就各州的公平执行提出建议。 The coalition, formed after input from over 120 stakeholders, will evaluate new conditions for screening using science-based, transparent processes and will advise on equitable implementation across states. 它将进行公开评论,公布详细的建议。 It will conduct public comment periods and publish detailed recommendations. 与此同时,俄勒冈州的长期新生儿血点筛查计划 — — 对超过99%的婴儿进行超过45种可治疗条件的检测 — — 继续通过早期发现和快速干预拯救生命,并在24小时内获得结果。 Meanwhile, Oregon’s long-standing newborn bloodspot screening program, which tests over 99% of infants for more than 45 treatable conditions, continues to save lives through early detection and rapid intervention, with results available within 24 hours.